19
total announcements
ANUHPHR.NS · 15 min delayed
Anuh Pharma Limited
Anuh Pharma Limited has released its Q1 FY 2027 investor presentation, showcasing a confident start to the year with profit growth outpacing revenue, driven by a richer product mix, disciplined cost control, and better throughput from existing assets. The company has secured USFDA and EU GMP clearances, positioning it for growth in regulated markets.
Anuh Pharma Limited
Anuh Pharma Limited has informed the Exchange about change in Management. The Company has reappointed Mr. Bipin Nemchand Shah and Mr. Arun Lalchand Todarwal as Non-Executive Non-Independent Directors, and Mr. Ankit Kishor Chande as a Cost Auditor for the financial year ending March, 2027. The Company has also revised the remuneration payable to Mr. Ritesh B. Shah and Mr. Vivek Shah, and approved the adoption of new Memorandum of Association and Articles of Association.
Anuh Pharma Limited
Anuh Pharma Limited has informed the Exchange regarding the appointment of Mr. Bipin N. Shah, Mr. Arun L. Todarwal, and Mr. Ankit Chande as Directors of the company.
Anuh Pharma Limited
Anuh Pharma Limited has informed the Exchange about General Updates under Regulation 30, including the reappointment of two Non-Executive Directors, revision in remuneration of Joint Managing Directors, and adoption of new Memorandum of Association and Articles of Association.
Anuh Pharma Limited
Anuh Pharma Limited has submitted the Voting Results and Scrutinizers report of its 66th Annual General Meeting held on August 12, 2026. The meeting was conducted through Video Conferencing and had a total of 45 shareholders present, with 17 promoters and 28 public shareholders. The resolutions passed included the adoption of audited financial statements, declaration of a dividend of Rs. 1.50 per equity share, and the appointment of directors.
Anuh Pharma Limited
Anuh Pharma Limited has informed the Exchange regarding Proceedings of 66th Annual General Meeting held on August 12, 2026, where resolutions related to audited financial statements, dividend declaration, director appointments, and remuneration revisions were passed.
Anuh Pharma Limited
Anuh Pharma Limited has published unaudited financial results for the quarter ended June 30, 2026, in newspapers and on its website.
Anuh Pharma Limited
Anuh Pharma Limited has informed the Exchange regarding 'Adoption of Revised Policy of Related Party Transactions.' The company has also announced its unaudited financial results for the quarter ended 30th June, 2026, which show a profit of Rs. 1,142.49 lakhs.
Anuh Pharma Limited
Anuh Pharma Limited has received a request for withdrawal of an application for reclassification of shareholding from Promoter & Promoter Group to Public Category.
Anuh Pharma Limited
Anuh Pharma Limited has announced its unaudited financial results for the quarter ended 30th June, 2026, showing revenue from operations of Rs. 19,381.04 lakhs, a 9.22% increase from the previous quarter, and a net profit of Rs. 1,142.49 lakhs.
Anuh Pharma Limited
Anuh Pharma Limited has submitted its unaudited financial results for the quarter ended June 30, 2026, which were reviewed by the Audit Committee and approved by the Board of Directors. The results show a profit before tax of Rs. 1,692.81 lakhs, a 10.4% increase from the same quarter last year. The company's earnings per equity share for the quarter is Rs. 1.14.
Anuh Pharma Limited
Anuh Pharma Limited has dispatched physical communications to shareholders who have not registered their email addresses and informed about the 66th Annual General Meeting and availability of the Annual Report for the financial year 2025-26.
Anuh Pharma Limited
Anuh Pharma Limited has informed the Exchange about the publication of a newspaper advertisement regarding the Notice of the 66th Annual General Meeting, Book Closure, and e-voting information.
Anuh Pharma Limited
Anuh Pharma Limited has informed the Exchange regarding Notice of Annual General Meeting to be held on August 12, 2026, to consider various resolutions including adoption of audited financial statements, declaration of dividend, re-appointment of directors, and revision in remuneration of a joint managing director.
Anuh Pharma Limited
Anuh Pharma Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018, confirming no dematerialization of equity shares during the quarter ended 30th June 2026.
Anuh Pharma Limited
Anuh Pharma Limited has closed its trading window for insiders and designated persons from July 1, 2026, until 48 hours after the declaration of its un-audited financial results for the quarter ended June 30, 2026, as per SEBI regulations.
ANUHPHR
ANUHPHR announced a clarification regarding a recent newspaper publication concerning the transfer of equity shares to the Investor Education and Protection Fund (IEPF). The company identified two inadvertent errors in the website addresses published. The correct company website is `www.anuhpharma.com` (instead of `www.anuhapharma.com`), and the correct IEPF website is `www.iepf.gov.in` (instead of `www.efo.gov.in`). This correction ensures investors have access to accurate online resources for information related to IEPF share transfers.
Anuh Pharma Limited
Anuh Pharma Limited has informed the stock exchanges about receiving a Demand Order and a Penalty Order from the Income Tax Department. These orders, issued under Sections 156 and 270 of the Income Tax Act, 1961, are a result of a scrutiny assessment for the Assessment Year 2020-21. Crucially, the announcement does not disclose the monetary value of the demand or penalty. Therefore, investors cannot currently ascertain the specific financial impact or potential liability on the company.
Anuh Pharma Limited
Anuh Pharma Limited has announced the publication of newspaper advertisements regarding the proposed transfer of specific equity shares to the Investor Education and Protection Fund (IEPF). This transfer applies to shares for which dividends have not been claimed by shareholders for seven consecutive years or more. The company is undertaking this action in compliance with the Investor Education and Protection Fund Authority regulations. This announcement serves as a final notice for affected shareholders. Investors holding such shares are advised to review their records and take necessary steps to claim their dividends or shares to prevent the transfer.